Relebactam

DRUG2 trials

Sponsors

Hellenic Institute For The Study Of Sepsis, Merck Sharp & Dohme LLC

Conditions

Bacterial PneumoniaSevere infections

Phase 3

Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)

CompletedNCT02493764

Merck Sharp & Dohme LLCBacterial Pneumonia

Start: 2015-11-24End: 2019-04-03Updated: 2020-04-16

A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE INFECTIONS (The MODIFY trial)

Active, not recruitingCTIS2022-502962-26-00

Hellenic Institute For The Study Of SepsisSevere infections

Start: 2023-09-14Target: 190Updated: 2025-11-03

Related Papers

Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study.

2026-01-26

Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis

Open Forum Infectious Diseases2023-05-043 citations

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

Clinical and Translational Science2021-10-2730 citations

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Clinical Infectious Diseases2020-07-06211 citations